Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor–Induced Cutaneous Squamous Cell Carcinoma
Articolo
Data di Pubblicazione:
2013
Citazione:
Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor–Induced Cutaneous Squamous Cell Carcinoma / Viros, Amaya; Hayward, Robert; Martin, Matthew; Yashar, Sharona; Yu, Clarissa C.; Sanchez Laorden, Berta; Zambon, Alfonso; Niculescu Duvaz, Dan; Springer, Caroline; Lo, Roger S; Marais, Richard. - In: JOURNAL OF INVESTIGATIVE DERMATOLOGY. - ISSN 0022-202X. - 133:1(2013), pp. 274-276. [10.1038/jid.2012.268]
Abstract:
We tested the efficacy of 5-FU on secondary SCC in two melanoma patients who were being treated with the BRAF inhibitor dabrafenib (GSK2118436). We show that 5-FU provides a safe, noninvasive, inexpensive, and effective alternative to surgical intervention in clinical cases in which multiple surgeries are difficult or in cases in which lesions are incipient.
Tipologia CRIS:
Articolo su rivista
Keywords:
9,10-Dimethyl-1,2-benzanthracene; Administration, Topical; Animals; Antineoplastic Agents; Carcinogens; Carcinoma, Squamous Cell; Cell Line; Cell Proliferation; Fluorouracil; Humans; Imidazoles; Indoles; Melanoma; Mice; Oximes; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Tetradecanoylphorbol Acetate; 2708; Biochemistry; Cell Biology; Molecular Biology
Elenco autori:
Viros, Amaya; Hayward, Robert; Martin, Matthew; Yashar, Sharona; Yu, Clarissa C.; Sanchez Laorden, Berta; Zambon, Alfonso; Niculescu Duvaz, Dan; Springer, Caroline; Lo, Roger S; Marais, Richard
Link alla scheda completa:
Pubblicato in: